Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

International phase III trial of Maxamine in malignant melanoma

Nov. 18, 1997

Evidence that Theratope elicits an antitumor cellular immune response presented

Nov. 18, 1997

FDA approves Intron A for non-Hodgkin's lymphoma

Nov. 12, 1997

AntiVirals to acquire ImmunoTherapy and its late-stage cancer vaccine

Nov. 7, 1997

Phase I trials begin on TNT in glioma patients

Nov. 6, 1997

Novopharm Biotech cleared for phase I trials of melanoma immunotherapy

Oct. 30, 1997

Antitumor activity of LC-9018 correlated with cytokine production

Oct. 28, 1997

KRN-7000 for the treatment of liver metastasis

Oct. 23, 1997

Imutec's Virulizin approved in Mexico for malignant melanoma

Oct. 23, 1997

Update on development of NeoPharm's novel chimeric human protein

Oct. 21, 1997

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...